Speakers

Speakers Line-up

SPEAKERS

Jim Qiu
Executive Vice President
Wuhan YZY Biopharma
, China

Yuan Wen
Director of Process Development
WuXi Biologics, China
Yun Bai
Senior Director, Process Sciences and Manufacturing
Ambrx Inc, China
JuHong Liu
Acting Review Chief, Division of Biotechnology Review and Research II, OBP/OPQ/CDER
FDA
YuanSheng Yang
Staff Scientist
Bioprocessing Technology Institute, Singapore
Senyon Teddy Choe
Director/President, Mogam Institute for Biomedical Research, Korea & Professor
University of California, U.S.
James (Jianguo) Yang
President/CEO
Abpro-China, China and U.S.
Yves Durocher
Section leader of Mammalian Cell Expression, Human Health Therapeutics Portfolio, National Research Council Canada & Assistant Professor, Department of Biochemistry
University of Montreal,
Canada
QiWei Wu
Vice PresidentTechnical Operation, Process Development
Mabspace Biosciences Co. Ltd., China
Lisa Shen
Head of R&D Department of Genetic Engineering
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.,
 China

Rolf G. Werner
Professor
University Tuebingen,
Germany

MinMin Qin
Director/CSO, Technology Center for Antibody Therapeutics, National Translational Medicine Center for Molecular Medicine (Xian) & Distinguished Professor, Fourth Military Medical University, China 
WeiDong Jiang
CSO and Vice President
Henlix Biopharmaceuticals

Andy Tsun
Director, Director of Functional Biology, Drug Discovery
Innovent Biologics Inc, China

Jason Li
Vice President, Manufacturing
Genor Biopharma, China

John (XianFang) Zeng
Executive Vice President
Shanghai Zerun Biotechnology, China
Billy Cho
Director of Healthcare, Asia Pacific
Citi Bank, Hong Kong
 

PLENARY SPEAKERS

Qian Xue Ming
CEO
Mabspace Biosciences, China 
Joe Zhou
CEO
Genor Biopharma, China
Fu Daotian
General Manager
Livzon Mabpharm, China
Ming Wang
President and CEO
Phanes Biopharmaceuticals, U.S. and China
Wu Youling
CEO
Zhejiang Teruisi Pharmaceutical, China
Li Shi
CEO
Shanghai Zerun Biotechnology Co. Ltd, China
Zhu Xiang Yang
CEO
Huabo Biopharm (Shanghai) Co. Ltd, 
China
James (Jianguo) Yang
President/CEO
Abpro-China, China and U.S.
Wu Chengbin
CEO
EpimAb Biotherapeutics Co. Ltd, China
 

Sponsors

Scott J. Jacobia
Associate Director, R&D
Thermo Fisher Scientific, U.S.

Jessie H.-T. Ni, Ph.D.
Chief Scientific Officer
Irvine Scientific

David Han
Head of Upstream & System RD China
Merck

Frank Li
Associate Manager of Upstream Process Development, APAC End to End\ Biodevelopment Delivery
Merck
Timothy Xia
Vice President
GenScript Co., Ltd.
Eleni Mumtsidu
Director of Cell Culture Media
Sartorius Stedim Biotech, Asia
SongHooi Teh
Lead Scientist
Lonza, Singapore
Keith Breinlinger
VP Engineering
Berkeley Lights, Inc

 

Speakers Profile

SPEAKERS

JuHong Liu
Acting Review Chief, Division of Biotechnology Review and Research II, Office of Biotechnology Products, Office of Pharmaceutical Quality
CDER,
FDA, U.S.

Dr. Juhong Liu received his Ph.D. in Biochemistry and Molecular Biology in Peking Union Medical College.  He obtained research training as a post-doctoral and latterly as a staff scientist in Laboratory of Pathology of the National Cancer Institute where he worked on characterization of transcription factors.  He joined the Division of Therapeutic Proteins, Office of Biotechnology Products (OBP) in 2008 and is now a Lead Biologist in Division of Biotechnology Review and Research II of OBP.  He has involved in reviews of regulatory submissions of a variety of protein products, including monoclonal antibodies, enzyme replacement therapy products, cytokines, and hormones.


James (Jianguo) Yang
President/CEO
Abpro-China, China and U.S.

Dr. James (Jianguo) Yang has over 20-year extensive experience in biopharma industry (from RD to commercial projects). Currently, Dr. Yang is President / CEO Abpro-China ( Abpro, a Biotech company based in Boston area, USA). Before joining Abpro, Dr. Yang was CSO / VP Biologics in Qilu Pharmaceuticals, and also had scientific leadership positions in several global 500 pharmaceutical companies, including in Abbott Lab Pharma Division (current AbbVie), MedImmune /AstraZeneca, Genzyme / Sanofi.  Dr. Yang has published numerous patents and scientific papers, and is an editor advisor and reviewer for Bioprocess International (Journal), and Executive Director, Sino-America Pharmaceutical Association-NE (2012-2014), and reviewer for several scientific journals. As international recognized scientist in biopharma Industry, Dr. Yang is a frequently-invited speaker for international biotech/biopharma conferences. Dr. Yang got his Ph.D. in cell/molecular biology from Illinois Institute of Technology, USA.


Jim Qiu
Executive Vice President
Wuhan YZY Biopharma
, China

Jiangxi medical university medical doctor,The university of Pennsylvania school of medicine, a postdoctoral fellow,  John Hopkins university MBA.

1994-1996 as the ambassador of Pennsylvania university school of medicine department of pathology, laboratory director, 1996-1998 Syncomm company vice President, 1999-2000 is the GSK of pharmaceutical and biological pharmaceutical sector, a senior scientist,  2000-2005 is in Rockville human genome sciences senior project director, 2005-2012 senior managers MedImmune technology development of the company,  from 2012 to 2015 of WuXi App Tec biological agents and biological technology department. In the field of process development, pilot magnification and biological agents have very rich experience in technology and management.


WeiDong Jiang
CSO and Vice President
Henlix Biopharmaceuticals

Dr. Weidong Jiang is a cofounder of Henlius Biopharmaceuticals, Inc. in U.S. He is also Senior Vice President and Chief Scientific Officer of Shanghai Henlius Biotech Co., Ltd., a joint venture formed by Henlius and Fosun Pharma in 2009 to develop antibody therapeutics.  Dr. Jiang has more than 20 years of experience in many biotech companies, including Catalyst Biosciences Inc., Vasgene Therapeutics Inc., Applied Molecular Evolution Inc. (subsidiary of Eli Lilly), Microcide, and Chemgenics (acquired by Millennium). He has expertise in the field of drug screening and development, particularly in research and development of antibody therapeutics and other protein biologics. He holds a Ph.D. degree from Giessen University in Germany, a Master degree from Shanghai Institute of Cell Biology, Chinese academy of Sciences, and a Bachelor degree from Zhejiang University.


QiWei Wu
Vice PresidentTechnical Operation, Process Development
Mabspace Biosciences Co. Ltd., China

Dr. Wu has more than 15 years of industry experience in CMC development of monoclonal antibodies, recombinant proteins.  In the past few years, his interest focus on building the CHO-based monoclonal antibody technology platforms for biosimilar and biobetter therapeutics in China.   Dr. Wu is currently Vice President of Technical Operation, Process Development at Mabspace Biosciences at Suzhou, China.   Priot to this position,  Dr. Wu hold several scientific and executive position with Fujian Haixi Pharma,  Henlius Biopharmaceuticals and Abgneix (Now Amgen), play the key role in the process development, scale-up, analytical development, pilot plant operation, supply chain, etc.  Dr. Wu graduated from Xiamen University, has a Ph.D. in Molecular Biology from Simon Fraser University, Canada and completed his postdoctoral fellowship at Stanford University Medical School. 


Senyon Teddy Choe
Director/President, Mogam Institute for Biomedical Research, Korea & Professor
University of California, U.S.

Senyon Teddy Choe is a Director of Mogam Institute, Korea, and a Professor of Biology at UCSD since 1993. Prior to Mogam Institute, he was a founding faculty member of Structural Biology Laboratory of Salk Institute from 1993 to 2015. His major honors include election in 1999 to the Fellow of American Association for the Advancement of Science (AAAS) in recognition for his frontier science in biophysics of K channels and of TGF-beta ligands. He has studied Biophysics and Medical Physics in the laboratory of Dr. Robert Stroud (UCSF) and received his Ph.D from University of California, Berkeley. His research group focused on molecular mechanisms of cell-cell communication to develop new stem cell therapy and the drug discovery. With a particular focus on TGF-beta superfamily ligands, he developed synthetic protein therapeutics against bone disorders and fibrosis. He is a sought-after speaker at public events including his recent TEDx lecture.


YuanSheng Yang
Staff Scientist
Bioprocessing Technology Institute, Singapore

Dr. Yuansheng Yang received his doctorate degree from Vanderbilt University’s Department of Chemical Engineering in 2005. Upon graduation, he joined the Animal Cell Technology group, Bioprocessing Technology Institute (BTI) in Singapore as a research scientist. He had been an adjunct assistant professor of Nanyang Technological University from 2012 to 2015. He currently leads a group working on vector design, cell line development, cell engineering, and bioprocess optimization to enhance the yield and quality of biopharmaceutical drugs produced using CHO cells. He has published over 40 papers and filed several patents related to developing cell lines for high level expression of monoclonal antibodies and other recombinant proteins.


Yun Bai
Senior Director, Process Sciences and Manufacturing
Ambrx Inc, China

Dr. Yun Bai is senior director of process sciences and manufacturing at Ambrx Inc. and responsible for process development including cell culture process, purification process, conjugation process development as well as analytical assay development, formulation development for biological products, process transfer to contract manufacturing organizations and support tox and clinical manufacturing at CMO sites for products derived from both microbial and mammalian expression systems. Dr. Bai has worked in biotech industry for 16 years, and holds B.A, M.S. and Ph.D degrees in Chemical Engineering, specializing in Biochemical Engineering.


Yves Durocher
Section leader of Mammalian Cell Expression, Human Health Therapeutics Portfolio, National Research Council Canada & Assistant Professor, Department of Biochemistry
University of Montreal,
Canada

Yves Durocher obtained his PhD in Biochemistry at the Universite de Montreal in 1993. He joined the NRC in 1995 and was in charge of industrial projects with bio/pharmaceutical companies for the production of membrane receptors and recombinant proteins for various drug discovery projects. Yves manages a section of 33 members involved in protein expression and CHO cell line development for internal projects and external clients. His research activities focus on improving large-scale transient gene expression (LSTGE) platforms using HEK293 and CHO cells for protein production and on developing and engineering a stable CHO pool and clonal cell line platform for recombinant protein manufacturing. Yves is also an assistant professor at the Department of Biochemistry at the University of Montreal.
Contact: yves.durocher@nrc.gc.ca


Rolf G. Werner
Professor
University Tuebingen,
Germany

Prof. Dr. Dr. Rolf G. Werner is Honorary Senator of University of Tuebingen and teaching Industrial Biotechnology. He is one of the worldwide leading experts in the area of research, development and production of safe and efficient biopharmaceuticals with more than 3 years in academia at Max Planck Institute for Molecular Genetics, Berlin, Germany and Massachusetts Institute for Technology, Cambridge, USA and more than 35 years experience at Boehringer Ingelheim in top leading positions. More than 20 therapeutic proteins and monoclonal antibodies have been developed, manufactured and regulatory approved under his responsibility. He is consulting biopharmaceutical and vaccine companies in Europe and Asia in all aspects of research and production technologies. His achievements are honored for outstanding scientific work from the Hangzhou Government, China, as Hangzhou Qian Jiang Distinguished Expert in Biotechnology. He is Member of International Advisory Committee of Translational Science Center for Molecular Medicine, X’ian, China. 


MinMin Qin
Director/CSO, Technology Center for Antibody Therapeutics, National Translational Medicine Center for Molecular Medicine (Xian) & Distinguished Professor, Fourth Military Medical University, China 

Dr. Qin graduated from UW-Madison with his Ph. D. in Genetics/Molecular Biology in 1991 and did his postdoctoral research at UC Berkeley.  Dr. Qin was a founding member of BioMarin with his last position as Senior Director of Process Sciences.  Dr. Qin joined Five Prime Therapeutics in 2005 as Senior Director of Process Development and started Shanghai JMT-Bio as CTO/SVP in 2012.  He then served as CTO/SVP of Zhejiang Teruisi from 2015-2016. Dr. Qin is currently Director/CSO, Technology Center for Antibody Therapeutics in National Translational Medicine Center for Molecular Medicine (Xian), and Distinguished Professor, Fourth Military Medical University.  Dr. Qin has many years of first-hand experience in successful development and commercialization of biopharmaceuticals including extensive experience in working with US FDA and EMA.  Dr. Qin is also a distinguished scholar with numerous publications in Nature, Science, Science Translational Medicine, PNAS etc. and is specialized in various expression technologies for antibodies and complex glycoproteins in mammalian systems.


Lisa Shen
Head of R&D Department of Genetic Engineering
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.,
 China

Lisa Shen was born in Shanghai in 1976. She received the B.S. degree in Biochemistry from Shanghai University, the M.E. degree in Microbiology from the Second Military Medical University, and Ph.D. in Biology and medicine from Fudan University. She joined Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (FDZJ), Shanghai, China, in 1998. She is currently the head of R&D Department of Genetic Engineering of FDZJ. She has over 15 years of biologics development experience in biopharmaceutical industry. Her main areas of research interest are cell line development, cell culture process development, and MOA study of therapeutic antibodies including monoclonal antibodies, antibody-drug conjugates and Fc fusion proteins.


Yuan Wen
Director of Process Development
WuXi Biologics, China

Dr. Wen currently leads Cell Culture Process Development at the Wuxi site of WuXi Biologics. He and his team work on various projects from IND enabling process development to clinical MFG support and late phase process characterization. He previously worked as Staff Scientist and then Process Science Manager in the R&D and BD teams of Gibco medium services at Thermo Fisher Scientific (previously Life Technologies Corp.). He has extensive experiences in cell culture medium, process, and tool development. He got his Ph.D. degree in Chemical Engineering from The Ohio State University, and B.S. degree in Bioengineering from Zhejiang University.


Andy Tsun
Director, Director of Functional Biology, Drug Discovery
Innovent Biologics Inc, China

Andy Tsun currently leads the functional biology team and previously led the cell line development group at Innovent Biologics, where he is involved in final lead candidate selection and characterisation of therapeutic biologics. Previously, he was a scientist at the Institut Pasteur of Shanghai working on CD4+ regulatory T cells, and obtained his PhD from University of Oxford studying the cell biology of CD8+ cytotoxic T cells.


Jason Li
Vice President
Genor Biopharma, China

Jason Li has been with Genor Biopharma for 9 years. He has led the efforts of process development, preclinical studies, pilot plant, clinical manufacturing, technology transfer and commercial manufacturing. He had worked in process development of Amgen Thousand Oaks. He majored in Chemical and Biochemical Engineering in Tianjin University as well as University of Maryland Baltimore County. 

 

PLENARY SPEAKERS

Joe Zhou
CEO
Genor Biopharma, China

Dr. Joe Zhou was invited to take the CEO position of the company on Oct of 2008. Previously, Dr. Zhou was Scientific Director at Amgen, Thousand Oaks, USA. His over 20-years experience of process development, multiple project management capacity in cGMP and non-GMP reproducible purification/production of protein/antibody therapeutics from FIH to CPD with depth knowledge of CHO clone selection, cell culture optimization, real time analytical assays, formulation and product specification for drug substances and drug products made Dr. Zhou many times as Project Process Team Leader/Project Team Leader/Cross Functional Core Investigation Teams Leaders at Amgen in the past.

Dr. Zhou has proven bio-industrial leadership in scientific innovation and technology evaluation, and is well known for implementation of membrane chromatography in mAb large-scale processing. Dr. Zhou has excellent reputation and an extended external network in the Process Development and or Process science peer community due to his extensive speaking and publication record including research articles, patents and book chapters in the Process Development and Process science field. Dr. Zhou has proven records for design space for process robustness and viral clearance in mAb production. Dr. Zhou was awarded as 2007 Amgen’s “Excellence n Science and Engineering” for his major achievement and leadership on photo-oxidation on monoclonal antibody yellowing, and selected by Amgen as a visiting professor teaching the GMP Master’s Degree Program at PKU, People’s Republic of CHINA since 2007.


Fu Daotian
General Manager
Livzon Mabpharm, China

Daotian Fu is Vice President & Managing Director of Livzon Pharmaceutical Group. He is also General Manager of Livzon MabPharm, Inc., an early stage biologics development company. Daotian received his BS from Shandong University in China, and his Ph.D. from Iowa State University. He also received post-doctoral training at University of Georgia in collaboration with Harvard Medical School. Prior to joining Livzon in May 2012, Daotian was Vice President at Genzyme, where he was responsible for the quality control and analytical development of all biologics at Genzyme. Daotian is the recipient of the National “1000 Talent” program.


Ming Wang
President and CEO
Phanes Biopharmaceuticals, U.S. and China

Dr. Ming Wang is Founder, President and CEO of Phanes Biopharmaceuticals, a biotech company focused on drug discovery and development to treat grievous diseases. The company is setting up R&D sites in both US and China. Ming is also leading the effort of building a biotech innovation park and forming a venture fund in Guangdong, China. Ming was formerly Vice President and Disease Area Leader of Diabetes/Metabolism at Janssen Pharmaceuticals of Johnson & Johnson. In this role, he was responsible for setting disease area strategies, making investment decisions and building a portfolio of assets for disease treatment and prevention. Under his leadership, J&J built a strong pipeline of metabolic assets through internal innovation and external partnerships, including a licensing agreement with Hanmi on a phase 1 clinical candidate with an upfront payment of $105 million last year. Previously, Ming was President and Chief Operating Officer and a member of the Board of Directors at Gan & Lee Pharmaceuticals, a biotech pioneer in China focused on insulin-based therapies with annual combined sales of ~$100 million in China, Latin America and Southeast Asia. Prior to that, Ming was Executive Director and Head of Diabetes Research at Amgen where he headed a group of ~50 scientists located on two research sites working on developing novel therapies for metabolic diseases. Before joining Amgen, Ming championed drug discovery programs in cardiovascular and metabolic diseases and managed corporate partnerships in Parke-Davis, Pfizer and Pharmacia.

Ming served on multiple advisory boards, including the Scientific Advisory Board (SAB) of Amgen Ventures ($100 million in management). He is a frequent organizer and speaker at biotech and pharma conferences and has 59 publications and a book entitled “Metabolic Syndrome: underlying mechanisms and drug therapies” (publisher: John Wiley & Sons, Inc.). He is Associate Editor for Frontiers in Experimental Pharmacology and Drug Discovery. Ming is also an adjunct faculty in the Department of Bioengineering and Therapeutic Sciences at the University of California, San Francisco Schools of Pharmacy and Medicine. He holds a PhD in Biochemistry and a MBA in General Management.


Wu Youling
CEO
Zhejiang Teruisi Pharmaceutical, China

Currently hold the CEO position of Zhejiang Teruisi Pharmaceutical Inc. that is located in Huzhou. Broad based experiences in biopharmaceutical companies and innovated biotech companies in multiple disciplinary functional areas: Company CEO, Analytical Development, Regulatory-CMC, and quality control involving variety disease areas. Participated in development and commercialization of six Blockbuster mono-antibodies, including Orencia, belatacept, Remicade, Stelera, Golimumab and Brentuximab.


Zhu Xiang Yang
CEO
Huabo Biopharm (Shanghai) Co. Ltd, 
China

Dr. Zhu is an expert in antibody drug discovery and process development with more than 17 years of industrial experience. He has extensive experience in antibody drug discovery, cell line and process development, and manufacture facility construction. Dr. Zhu is working at Huahai Pharm and led its global biological research as the CEO for Huaota Biopharmaceuticals and Huabo Pharmaceuticals (members of Huahai Pharm). Prior to join Huahai, he worked at Boehringer Ingelheim for more than 8 years in different function areas at multiple locations :( Ridgefield, USA; Biberach, Germany; and Shanghai, China). He led and engaged in over 20 global BI biological research projects including current clinic Phase I-III projects and market products; he also led and participated in up/downstream process development of multiple biological products as well as in the design and construction of the pilot plant at Shanghai. Dr. Zhu obtained his PhD in microbiology and immunology from theUniversity of Illinois at Chicago and has authored more than 20 publications in peer-reviewed journals.


Qian Xue Ming
CEO
Mabspace Biosciences, China 

Dr. Qian has been involved in antibody discovery and development for the past fifteen years. He is currently Chairman and CEO of MabSpace Biosciences, a startup biotech company he founded in 2013 and focused in discovering and developing well-differentiated therapeutic antibodies targeting both novel and clinically validated targets for the treatment of cancer and metabolic disorders.

Before starting MABSPACE, Dr. Qian was Senior VP and Head of R&D of Shenogen Pharma Group from 2010 and 2012, a Beijing-based biopharma company developing anti-cancer therapies. From 1997 and 2010 Dr. Qian worked at Amgen as Principal Scientist and led multiple project teams to discover novel antibody therapeutics. Dr. Qian is a member of the National 1000 Talent Program, BayHelix as well as several scientific organizations such as ASCO, ESMO, AACR and Antibody Society. He is the leading inventor of more than ten antibody patents or applications.

Sponsors

David Han
Head of Upstream & System RD China
Merck

David Han is the head of Upstream & System RD China at Merck. He is responsible for customized media development and process development in biologics areas and vaccine areas. He has more than ten years of industrial experience in biopharmaceutical industry, especially in CHO based recombinant protein drugs production from cell line generation to large scale production. Prior to joining Merck in 2014, David worked in AutekBio as the director of upstream process development and led a dozen of projects development. He obtained his PhD of Biotechnology and Pharmaceutical from Chinese Academy of Sciences, and his Bachelor of Biology from Shandong University.


Frank Li
Associate Manager of Upstream Process Development, APAC End to End\ Biodevelopment Delivery
Merck

Frank Li is the Associate Manager of Upstream Process Development of APAC End to End\ Biodevelopment Delivery at Merck. He is responsible for upstream process development, process validation and production using mammalian cells in biologics areas. He has strong biopharmaceutical industrial experience from cell line generation to large scale GMP production. He obtained his PhD of Pharmacy from Shanghai Jiao tong University.


Scott J. Jacobia
Associate Director, R&D
Thermo Fisher Scientific, U.S.

Scott received his PhD in Biochemistry from the University at Buffalo, The State University of New York and completed his post-doctoral training at the Institute for Human Gene Therapy at the University of Pennsylvania. Scott joined the R&D Department of Gibco in 2002. Scott was a Medium Development services team leader from 2005 – 2014 and the Cell Line Development services team leader in 2014. Currently, Scott is responsible for the Gibco Bioproduction Services team, which includes cell line development and medium/process development. His current efforts focus on mammalian cell line development for expression of recombinant therapeutic proteins for bio-industrial customers.


SongHooi Teh
Lead Scientist
Lonza, Singapore

Song Hooi is a team lead in Lonza Singapore’s Development Services department.  He joined Lonza 5 years ago, initially being involved in setting up the development facility, and subsequently taking various roles in the cell culture process development function where he delivered various projects such as cell line construction and upstream process development. As a team leader, Song Hooi now holds responsibility for a group of upstream scientists who deliver multiple activities for Lonza’s customers.  Prior to joining Lonza, he worked in drug development focusing on target identification/target validation in the pharmaceutical sector.


Timothy Xia
Vice President
GenScript Co., Ltd.

Timothy Xia is the current Vice President, Protein Sciences at GenScript.  He joined the company in 2008, and has been responsible for protein/biologics expression, bioprocessing and functional analysis.  Prior to joining GenScript, Dr. Xia had been associated with Sanofi and its legacy companies for over 10 years conducting recombinant protein and biologics production for early drug discovery and development.  He also worked at Viral Therapeutics Inc. for 5 years before Sanofi for vaccine subunit production and development


Jessie H.-T. Ni, Ph.D.
Chief Scientific Officer
Irvine Scientific

Jessie Ni received her Ph.D. in Molecular Biology and post-doctoral training in Immunology from University of Minnesota.  She also has a Master of Management of Technology degree from Carlson School of Management, University of Minnesota.  Jessie owns expertise and track record in developing and commercializing reagents & technologies for life science applications. Before joining Irvine Scientific, Jessie spent more than 10 years in R&D Systems directing and managing the development and manufacturing of recombinant proteins, antibodies, and cell culture media, which helped to advance the biomedical research and application. Since joined Irvine Scientific in 2012, Jessie led the R&D team to develop improved chemically defined industrial cell culture media for major primary cell lines and primary cells, including CHO, MDCK/Vero, HEK293, mesenchymal stem/stromal and T cells.


Eleni Mumtsidu
Director of Cell Culture Media
Sartorius Stedim Biotech, Asia

Eleni Mumtsidu is responsible for leading the development of the Cell Culture Media and Buffers range in ASIA| PAC. She holds a PhD in Cell Biology Tumor Virology from the University of Heidelberg, Germany and a MBA from the City College of Athens.

She joined Sartorius-stedim biotech GmbH with successful experience in Cell Culture Facility management at EMBL, International Product & Marketing management at TECAN and R&D leadership positions at PerkinElmer and GE Healthcare. She has a strong background in Cell Culture Media and cell-based Assay Developments as to Cell & Protein Engineering and Protein Expression, Purification and Characterization Technologies.


Keith Breinlinger
VP Engineering
Berkeley Lights, Inc

Keith Breinlinger is the VP of Engineering at Berkeley Lights, Inc in Emeryville CA. Berkeley Lights manufactures advanced optofluidic platforms to enable faster and more efficient Antibody Discovery and Cell Line Development through the use of optical manipulation of single cells. Keith and his team are actively engaged in [ADD HERE or REMOVE PRECEDING CLAUSE] Before joining Berkeley Lights, Keith worked in the semiconductor equipment industry for 17 years at Teradyne and then FormFactor, developing complex engineering systems. He received his BS, MS and PhD from MIT in Mechanical Engineering focused on high precision design and MEMS. While at MIT, Keith worked on various robotic systems including, RoboTuna, RoboPike and the 2.70 robot competition. As an early employee, at iRobot, he worked on a cement leveling robot and a 6-legged walking robot. Keith holds 21 patents for devices ranging from coffee makers to high performance electrical connectors.